Thyroid Hormone Mimetics: the Past, Current Status and Future Challenges
Current Atherosclerosis Reports, ISSN: 1534-6242, Vol: 18, Issue: 3, Page: 1-6
2016
- 26Citations
- 68Captures
- 2Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations26
- Citation Indexes26
- 26
- CrossRef10
- Captures68
- Readers68
- 68
- Mentions2
- News Mentions2
- 2
Most Recent News
Synthetic thyroid hormone may lower cholesterol, treat obesity
Share on PinterestA thyroid hormone-mimicking drug delivered straight to the liver may reduce cholesterol levels and reverse obesity. Image credit: Alan Powdrill/. More than 1
Review Description
The association between thyroid hormone status and plasma levels of low-density lipoprotein cholesterol has raised the awareness for the development of thyroid hormone mimetics as lipid-lowering agents. The discovery of the two main types of thyroid hormone receptors (α and β) as well as the development of novel combinatorial chemistry providing organ specificity has drastically improved the selectivity of these compounds. In the past decades, several thyroid hormone mimetics have been investigated with the purpose of lowering low-density lipoprotein cholesterol levels. However, until now, none of the thyromimetics reached the stage of completing a phase III clinical trial without deleterious side effects. Here, we review the currently available literature on thyromimetics investigated for the treatment of dyslipidemia, their rise, their downfall and the challenges for the development of novel agents.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84958778701&origin=inward; http://dx.doi.org/10.1007/s11883-016-0564-7; http://www.ncbi.nlm.nih.gov/pubmed/26886134; http://link.springer.com/10.1007/s11883-016-0564-7; https://dx.doi.org/10.1007/s11883-016-0564-7; https://link.springer.com/article/10.1007/s11883-016-0564-7
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know